Navigation Links
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
Date:2/27/2009

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of ongoing discussions with and submissions to regulatory authorities and the potential goals, progress, timing and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential inability to address questions raised by regulatory agencies and to receive approval for phase 2 trial design, the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that the phase 2 trial for AT2220 is not resumed in a timely manner, or at all, and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier clinical trials may not be predictive of future results. Additionally, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, and our other public filings with the Securiti
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... new report released today from the Institute of Medicine ... training opportunities to reduce barriers to the provision of ... of CPR and AED use by bystanders remain less ... even though evidence indicates that its use ... strongly supports the IOM,s recommendation to encourage training through ...
(Date:6/30/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/54fkmt/global_array ... "Global Array Instruments Market 2015-2019" report to ... market to grow at a CAGR of 12.48 ... array instruments market can be divided into three ... tissue microarrays and cell microarrays. This report covers ...
(Date:6/30/2015)...  Today, the National Mobility Equipment Dealers Association (NMEDA) ... Awareness Month Local Heroes Contest on National TV. The ... received 1.3 million votes. The sponsors for the wheelchair ... , and Valley Honda Dealers , with the ... Mobility International (VMI) and ElDorado Mobility .  ...
Breaking Medicine Technology:New Recommendations in Cardiac Arrest Protocol Advocate for Increased CPR and AED Training to Improve U.S. Survival Rates 2New Recommendations in Cardiac Arrest Protocol Advocate for Increased CPR and AED Training to Improve U.S. Survival Rates 3New Recommendations in Cardiac Arrest Protocol Advocate for Increased CPR and AED Training to Improve U.S. Survival Rates 4Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2NMEDA Announces National Contest Winners 2NMEDA Announces National Contest Winners 3
(Date:7/1/2015)... ... July 01, 2015 , ... These listings ... case management, placement, sober companionship and delivery to wilderness therapy or treatment facilities. ... and transporting clients with anxiety, ADHD, autism spectrum disorders, eating disorders, severe learning ...
(Date:7/1/2015)... ... July 01, 2015 , ... RF ... solutions, has partnered with WIU Crossroads School in safeguarding its staff and students ... (Alternative Education for Disruptive Youth) environment of Crossroads School heightens the potential for ...
(Date:7/1/2015)... ... July 01, 2015 , ... Professional Physical Therapy (“Professional”), ... and New Jersey, acquired South Bay Sports & Physical Therapy ("South Bay"), located ... this most recent member of the Professional family, patients can expect an expert ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... year, it has proven its continuing growth as a Master Franchisor. 1Heart Caregiver ... 17th, the Simi Valley Chamber of Commerce Ambassadors headed by Keith Mashburn, Pam ...
(Date:6/30/2015)... ... June 30, 2015 , ... America is in a health ... autism, dementia, auto-immune deficiencies, or obesity. Why? , The answer is simple and is ... America’s Leading Stress Expert, has successfully treated over one million patients and, for the ...
Breaking Medicine News(10 mins):Health News:All Kinds of Therapy – Announces New Partnership Feature, Therapeutic Experts 2Health News:WIU Crossroads School Chooses Help Alert Mobile Staff Duress Pendants from RF Technologies to Safeguard Staff and Students, De-escalate Altercations 2Health News:WIU Crossroads School Chooses Help Alert Mobile Staff Duress Pendants from RF Technologies to Safeguard Staff and Students, De-escalate Altercations 3Health News:Professional Physical Therapy Acquires Copiague’s South Bay Sports & Physical Therapy, P.C. 2Health News:1Heart Caregiver Services® Simi Valley Grand Opening 2Health News:1Heart Caregiver Services® Simi Valley Grand Opening 3Health News:1Heart Caregiver Services® Simi Valley Grand Opening 4Health News:12 Easy-To-Follow Steps to Transform Body, Mind and Spirit 2
... New Non-Steroidal Skin Treatment to Treat All ... with Steroids, BARRINGTON, Ill., Oct. 19 Steroids have ... abuse. There must be reasons why,people use steroid products on ... largest organ of the human body, and it needs to ...
... 19 Uroplasty, Inc. (Amex:,UPI) announced today that ... Securities and Exchange Commission in anticipation of a ... of its,common stock. Craig-Hallum Capital Group and ... connection with this proposed public offering.,A copy of ...
... Scans, Oct 26 & 27, as Part of Clinical Study., CHICAGO, ... Stage III or Stage IV ... at no charge as part of a clinical trial. ... cancer that tests positive for a protein called human ...
... Holdings, Inc. and its,operating subsidiary, US Oncology, Inc., ... November 8, 2007. A conference call and ... EST, for the company,s bondholders following the distribution ... US Oncology,s management,team will discuss the financial results. ...
... Oct. 18 West Pharmaceutical,Services, Inc. (NYSE: ... announcement that it has decided to discontinue marketing ... to the,Company,s customer, Nektar Therapeutics, Inc. The Company,s ... the Exubera inhalation device for Nektar. "We ...
... cancer patients with the poorest prognosis -- those with a ... may survive longer with a drug that chokes off ... by researchers at Dukes Preston Robert Tisch Brain Tumor Center, ... and a standard chemotherapy agent, may increase the amount of ...
Cached Medicine News:Health News:Steroids Are Abused for Skin, Not Just Muscles 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 3Health News:Brain Screenings Offered to Breast Cancer Patients During Breast Cancer Awareness Month 2Health News:West Pharmaceutical Services Issues Statement on Exubera 2Health News:West Pharmaceutical Services Issues Statement on Exubera 3Health News:West Pharmaceutical Services Issues Statement on Exubera 4Health News:Drug combination might offer hope for patients deadly brain tumors 2
Full Handle Laseredge Slit Blade Knife, 2.85 mm angled bevel up. Blade tip dimension: 14.4 mm x 2.8 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 2.8 mm angled double bevel. Blade tip dimension: N/A x 2.8 mm x N/A....
Full Handle Laseredge Slit Blade Knife, 2.5 mm angled bevel up. Blade tip dimension: 14.4 mm x 2.5 mm x 3.7 mm....
Full Handle Laseredge Implant Blade Knife, 5.7 mm round tip. Blade dimension: 16.5 mm x 5.7 mm x 4.2 mm x 2.4 mm....
Medicine Products: